Araştırma Makalesi

Does Lrig1 expression have a relationship with ERBB1 and ERBB2 expression in schizophrenia?

Cilt: 50 Sayı: 1 31 Mart 2025
PDF İndir
TR EN

Does Lrig1 expression have a relationship with ERBB1 and ERBB2 expression in schizophrenia?

Abstract

Purpose: This study aims to investigate Lrig1 expression and to reveal the possible relationship between Lrig1, ERBB1 and ERBB2 in schizophrenia. Materials and Methods: In this study, peripheral blood samples of 70 schizophrenia patients and 60 healthy controls were used. Real Time PCR was applied for Lrig1, ERBB1 and ERBB2 gene expression analysis. Results: The level of Lrig1 mRNA was lower in the patients when compared to healthy controls. Expression levels of ERBB1 and ERBB2 were decreased in the patients versus in the healthy controls. According to the receiver operating characteristic curve analysis, the three genes had the power to discriminate the patients from the healthy controls (Lrig1 AUC: 0.66, ERBB1 AUC: 0.64, ERBB2 AUC: 0.79). There was a weak, positive correlation between the Lrig1 and ERBB1 expressions in the schizophrenia patients. No significant correlation was detected between the Lrig1 and ERBB2 expressions or the ERBB1 and ERBB2 expressions in the patients. Conclusion: The results revealed that the Lrig1 and ERBB relationship changes in schizophrenia. These genes may have the potential to be a biomarker that can be used in schizophrenia.

Keywords

Schizophrenia , Lrig1 , ERBB1 , ERBB2 , EGFR

Kaynakça

  1. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119-36.
  2. Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr Bull. 2011;37:504-13.
  3. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway K et al. The Leucine-rich repeat protein LRIG1 Is a negative regulator of ERBB family receptor tyrosine Kinases. J Biol Chem. 2004;279:47050-6.
  4. Alsina FC, Hita FJ, Fontanet PA, Irala D, Hedman H, Ledda F et al. Lrig1 is a cell‐intrinsic modulator of hippocampal dendrite complexity and BDNF signaling. EMBO Rep. 2016;17:601-6.
  5. Karabulut Uzunçakmak S, Şahin A, Tavaci Özçelik A, Halici Z. LRIG1 levels in chronic rhinosinusitis with nasal polyps. Cukurova Med J. 2023;48:323-9.
  6. Ji Y, Kumar R, Gokhale A, Chao H, Rycaj K, Chen X et al. LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor. Semin Cancer Biol. 2022;82:120-33.
  7. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 2004;23:3270-81.
  8. Hita FJ, Bekinschtein P, Ledda F, Paratcha G. Leucine‐rich repeats and immunoglobulin‐like domains 1 deficiency affects hippocampal dendrite complexity and impairs cognitive function. Dev Neurobiol. 2021;81:774-85.
  9. Abe Y, Namba H, Zheng Y, Nawa H. In situ hybridization reveals developmental regulation of ERBB1-4 mRNA expression in mouse midbrain: implication of ERBB receptors for dopaminergic neurons. Neuroscience. 2009;161:95-110.
  10. Iwakura Y, Nawa H. ERBB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and parkinson’s disease. Front Cell Neurosci. 2013;7:4.

Kaynak Göster

MLA
Karabulut Uzunçakmak, Sevgi, vd. “Does Lrig1 expression have a relationship with ERBB1 and ERBB2 expression in schizophrenia?”. Cukurova Medical Journal, c. 50, sy 1, Mart 2025, ss. 221-30, doi:10.17826/cumj.1624159.